KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Operating Expenses: 2018-2025

Historic Operating Expenses for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to $89.8 million.

  • Castle Biosciences' Operating Expenses rose 11.33% to $89.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $378.5 million, marking a year-over-year increase of 20.95%. This contributed to the annual value of $323.4 million for FY2024, which is 12.38% up from last year.
  • Castle Biosciences' Operating Expenses amounted to $89.8 million in Q3 2025, which was down 0.65% from $90.4 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Operating Expenses high stood at $115.9 million for Q1 2025, and its period low was $24.1 million during Q1 2021.
  • Over the past 3 years, Castle Biosciences' median Operating Expenses value was $80.7 million (recorded in 2024), while the average stood at $82.5 million.
  • Data for Castle Biosciences' Operating Expenses shows a peak YoY surged of 139.07% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Castle Biosciences' Operating Expenses stood at $40.2 million in 2021, then soared by 52.13% to $61.2 million in 2022, then climbed by 17.34% to $71.8 million in 2023, then climbed by 14.60% to $82.3 million in 2024, then climbed by 11.33% to $89.8 million in 2025.
  • Its Operating Expenses stands at $89.8 million for Q3 2025, versus $90.4 million for Q2 2025 and $115.9 million for Q1 2025.